Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Cancer Immunotherapy / Immuno-Oncology & Non-small-cell lung cancer (NSCLC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Cancer Immunotherapy / Immuno-Oncology & Non-Small-Cell Lung Carcinoma (NSCLC) means for:

Non-Small-Cell Lung Carcinoma (NSCLC)

Non-Small-Cell Lung Carcinoma (NSCLC) (EGFR m.)

Non-Small-Cell Lung Carcinoma (NSCLC) (KRAS m)

Matching adjusted indirect comparison results demonstrated comparable effectiveness between pembrolizumab monotherapy and nivolumab + ipilimumab as first-line therapies for metastatic [non-small-cell lung cancer](brain://j0-uv_ewnUKCSIhKnUrTfQ/NonSmallCellLungCarcinomaNscl…

References (Sources)

A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study
Varlotto et al. 2021
Review
Challenges of Immunotherapy in Stage IV Non–Small-Cell Lung Cancer
Stock-Martineau et al. 2021 JOP 17: 465-471
Review
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Zhou et al. 2019 J Immunother Cancer 7(1): 120
Keeping it real: implications of real-world treatment outcomes for first-line immunotherapy in metastatic non-small-cell lung cancer
Hsu et al. 2021 Immunotherapy 13(18): 1453-1456
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri et al. 2023 Mol Cancer 22: 40
Review
New developments and updates in non-small cell lung cancer and immunotherapy: adjuvant, neoadjuvant and advanced stages
Olivares-Hernández et al. 2023 Ann Transl Med 11(12): 423
Novel immunotherapy combinations in neoadjuvant non-small cell lung cancer (NSCLC): a better chance at cure?
Salter et al. 2024 Transl Lung Cancer Res 13(3): 673-677

AI Chat

7/1/2026

Chat with our artificial intelligence: